The 41-degree scorching sun in Yichang, Hubei Province was like fire. The Central Media Pilot Free Trade Zone interview team walked into the Chengdong U Valley (Yichang Biomedical Incubator) located in the Bio-Industrial Park of the Yichang Area of Hubei Pilot Free Trade Zone, and not only felt the high temperature here , and also felt the burst of innovative vitality here from biological preparations, new drug research and development, medical devices and other aspects.

Chengdong U Valley is a biomedical professional incubation platform integrating entrepreneurial incubation, enterprise acceleration, headquarters economy and service support. The park focuses on the three sub-sectors of "biology, medicine and medical devices", and has formed an industrial development pattern driven by leading companies in the three sectors: biological preparations are led by Hubei Jingrui Tianheng Biotechnology; new drug research and development The category is led by "Kang Tai Pharmaceutical" founded by Dr. Li Qingshan; the medical device category is led by Dasi Medical.

"By introducing leading enterprises and driving the upstream and downstream supporting enterprises of their industrial chains to settle down, we will build a one-stop full-chain biomedical incubation system of 'Maker Space-Incubator-Accelerator-Industrial Park', integrate various innovation resources, and provide a platform for startups in the start-up stage. Enterprises provide shared facilities for R&D and office, so that enterprises in the park can supply and demand and influence each other, and realize upstream and downstream supporting cooperation, so as to gradually improve the industrial chain and further enhance the ability of scientific and technological innovation." Wu Peng, deputy general manager of Chengdong U Valley In an interview with reporters, Lu said that in the past five years, the park has introduced and cultivated more than 150 biopharmaceutical industry chain enterprises, including 23 national high-tech enterprises, 4 provincial-level specialized and special new "little giant" enterprises, and industry-specific enterprises. There is 1 "hidden champion" enterprise in different fields, more than 80 technology-based small and medium-sized enterprises in the warehouse, and 6 listed companies on the board. In 2021, the output value of the park will reach 1.356 billion yuan.

"U Valley in the east of the city" is just a microcosm of the development of the biomedical industry in the Yichang area. Since its listing in 2017, the Yichang area has been developing for five years, and has stimulated innovation vitality through the innovation and technology incentive mechanism.

"We use the shared thinking to revitalize the stock innovation resources, launch the 'enterprise technology innovation sharing service', promote the sharing of the innovation resources of leading enterprises to the society, and form a group of enterprise technology sharing service centers. Only in the field of biomedicine, we have promoted 1,300 technical personnel from leading enterprises. Talents and more than 3,300 sets of equipment worth 1.4 billion yuan are shared with the society." Fu Yan, a member of the Party Working Committee in Yichang area, said that at the same time, Yichang area also took the lead in implementing the "double-through" evaluation of skills and specialized talents, independent evaluation of professional titles, and professional title content. Reform measures such as the lack of evaluation have stimulated the innovation vitality of talents.

Not only that, the Yichang area has also successively introduced preferential policies for enterprises to attract and stabilize talents, newly introduced talent allowances for full-time doctoral (master) postgraduates, and grants for internship training subsidies for college students. Last year, the key enterprise high-end talent award declaration policy was introduced to reward key enterprises approved by the Yichang area (high-tech zone) engaged in scientific and technological research and development and transformation of scientific and technological achievements, international investment and trade, financial capital services, cross-border services and other fields. high-end talents.

This series of policies to attract and stabilize talents has provided support for the development of enterprises in the park, the introduction of high-level talents, and the retention of high-end talents. Among them, Yichang Renfu Pharmaceutical Company was deeply impressed.

"Since 2020, we have recruited and introduced 3,082 talents of all kinds, including 1,476 with bachelor's degree, 269 with master's degree, and 8 with doctor's degree." Yan Tao, deputy secretary of the company's party committee and vice president, told reporters that in order to allow various types of talents All employees have good development space. The company introduced a qualification system and designed a dual-channel development path of "management and technology", so that both types of employees who are suitable for "cadre" and "drilling skills" have a smooth development path. The establishment of the job qualification system clarifies the talent evaluation criteria, helps enterprises to effectively identify outstanding talents, enhances the reasonable and effective allocation of professionals, and also helps employees to clarify their career development channels. Excellent management talents with leadership potential can take the "management" path and be included in the company's reserve cadre database for training; professionals who are suitable for technology can take the "technical" path and concentrate on technology.

Of course, the development dividends given by the Yichang area do not stop there. Renfu Pharmaceutical is a company that insists on implementing its internationalization strategy. The Fentanyl Citrate Injection and Sufentanyl Citrate Injection produced by its small-volume injection workshop are the top export products. In 2021, the company's overseas market sales revenue will exceed 375 million yuan, of which 5 products rank among the top three in the US market share.

"In the five years since the establishment of the Yichang area, we have received a lot of policy support. For example, in the process of exporting our products to the world, the area has given support to our products in customs clearance and tax incentives." Yan Tao said, based on the excellent development environment, At present, the global headquarters base of Renfu Pharmaceutical with a total investment of 6 billion yuan is under construction. The base will introduce the world's top design and construction teams, adopt the world's most advanced technology, technology and hardware facilities to build the world's most advanced R&D and production base for anesthesia and psychotropic drugs, and it will be fully completed and put into production in 2025.